Q3 2014 13F Holders as of 30 Sep 2014
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
15,656,921
-
Share change
-
-833,647
-
Total reported value
-
$302,653,761
-
Price per share
-
$19.33
-
Number of holders
-
80
-
Value change
-
-$45,141,249
-
Number of buys
-
48
-
Number of sells
-
46
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q3 2014
As of 30 Sep 2014,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
80 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,656,921 shares.
The largest 10 holders included
Essex Woodlands Health Ventures, Inc., FRANKLIN RESOURCES INC, FMR LLC, JPMORGAN CHASE & CO, Arrowpoint Asset Management, LLC, Polar Capital LLP, COLUMBIA WANGER ASSET MANAGEMENT LLC, ALLIANCEBERNSTEIN L.P., GOLDMAN SACHS GROUP INC, and RS INVESTMENT MANAGEMENT CO LLC.
This page lists
80
institutional shareholders reporting positions in this security
for the Q3 2014 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.